Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires Interferon-Alpha.

Scientists investigated the impact of a pegylated interferon-alpha conditioning and support regimen on the safety and efficacy of tumor infiltrating lymphocytes plus Nivolumab.